Meningioma

GT Medical Technologies, Inc. Presents Use of GammaTile Therapy is Increasing in Time Across Several Brain Tumor Types at the 28th Annual Scientific Meeting and Education Day at the Society of Neuro-Oncology (SNO)

Retrieved on: 
Friday, November 17, 2023

TEMPE, Ariz., Nov. 17, 2023 /PRNewswire/ -- GT Medical Technologies, Inc., a medical device company dedicated to improving the lives of patients with brain tumors, today announced an increase of clinical cases in the United States using its GammaTile® Therapy in patients diagnosed with several brain tumor types. The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.

Key Points: 
  • The data was presented at the Society for Neuro-Oncology (SNO) 28th Annual Meeting and Education Day taking place from November 15-19, 2023, at the Vancouver Convention Center in Vancouver, Canada.
  • GammaTile has been used in over 1,000 patients with both newly diagnosed malignant brain tumors and recurrent brain tumors since 2019 and has been used in different tumor types, including glioblastoma, brain metastasis and meningioma.
  • Currently, GammaTile is sponsoring 4 clinical trials including a multi-institute registry trial (NCT0442738) that includes quality of life as a study metric.
  • GammaTile Therapy is a Surgically Targeted Radiation Therapy (STaRT) that delivers immediate radiation and eradicates brain tumor cells before they can replicate post-surgery while helping to protect healthy brain tissue.

Ikena Oncology Shares Initial Positive and Differentiated Dose Escalation Data from IK-930 Phase I Trial and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

BOSTON, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the quarter ended September 30, 2023, and provided a corporate update. The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.

Key Points: 
  • The Company also shared initial data from twenty-six (26) patients treated in the ongoing dose escalation portion of the Phase I clinical trial of IK-930, a novel, oral, potent, and highly selective Hippo pathway inhibitor.
  • “This early look at the IK-930 dose escalation data strongly supports our differentiated approach to targeting the Hippo pathway.
  • Importantly, following the target biology and initially focusing on EHE has allowed us to observe clinical activity of IK-930 early in our dose escalation.
  • Twenty-six patients with a range of solid tumors were treated in the dose escalation portion of the study as of October 31, 2023.

Recursion Provides Business Updates and Reports Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023

Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.

Key Points: 
  • Revenue: Total revenue was $10.5 million for the third quarter of 2023, compared to $13.2 million for the third quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $29.2 million for the third quarter of 2023, compared to $19.5 million for the third quarter of 2022.
  • Net Loss: Net loss was $93.0 million for the third quarter of 2023, compared to a net loss of $60.4 million for the third quarter of 2022.
  • Net Cash: Net cash used in operating activities was $72.9 million for the third quarter of 2023, compared to net cash used in operating activities of $54.5 million for the third quarter of 2022.

Novocure and Stanford School of Medicine to Establish Tumor Treating Fields Research Program

Retrieved on: 
Thursday, October 12, 2023

Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.

Key Points: 
  • Novocure (NASDAQ: NVCR) today announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields (TTFields) Research Program.
  • The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms.
  • “We look forward to collaborating with Stanford Medicine to establish a research framework for preclinical and clinical development of TTFields,” said Moshe Giladi, Ph.D., Novocure’s Chief Science Officer.
  • At present, Stanford Medicine is a site for four clinical studies of TTFields therapy.

Perspective Announces Presentation of Positive Early Clinical Data for VMT-α-NET at the 36th Annual Congress of the European Association of Nuclear Medicine

Retrieved on: 
Tuesday, September 12, 2023

Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.

Key Points: 
  • Responses observed in both peptide receptor radionuclide therapy-naïve and peptide receptor radionuclide therapy-refractory disease.
  • The results were presented at the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), held in Vienna, Austria, from September 9-13, 2023.
  • Improvements in patients’ symptoms and quality of life trended strongly positive with consecutive [212Pb]VMT-α-NET doses.
  • We will continue to monitor patients’ progress, and we look forward to providing a more extensive data readout in the upcoming quarters.”

Hoag Recruits Renowned Physician and Researcher from Dartmouth to Lead Hoag Neuro-Oncology Program

Retrieved on: 
Wednesday, August 30, 2023

NEWPORT BEACH, Calif. , Aug. 30, 2023 /PRNewswire/ -- Hoag is proud to announce that Simon Khagi, M.D., F.A.C.P., a renowned, triple board-certified medical oncologist and neuro-oncologist specializing in primary and metastatic brain cancers and spinal cord tumors, has joined the Hoag Family Cancer Institute as the director of neuro-oncology.

Key Points: 
  • Under Dr. Khagi's leadership, Hoag's Brain & Spine Tumor program will further its offerings in diagnosis, management and research, rivaling major academic medical centers.
  • "Dr. Khagi brings specialized expertise and research accomplishments that few physicians in the country can offer," said Burton Eisenberg, M.D., Grace E. Hoag Executive Medical Director Endowed Chair, Hoag Family Cancer Institute.
  • "His unique expertise in neuro-oncology is another example of how Hoag is highly committed to bringing the highest level of talent and innovation to our community."
  • Dr. Khagi joins Hoag after serving as regional medical director at Dartmouth Cancer Center in southern New Hampshire.

GT Medical Technologies Awarded the Arizona Bioscience Company of the Year for Disrupting the Status Quo in Brain Tumor Treatment

Retrieved on: 
Tuesday, August 15, 2023

Driven to improve the lives of patients with brain tumors, a group of brain tumor specialists and medical device experts joined forces to reimagine brain brachytherapy for operable glioblastomas (GBMs), meningiomas, and brain metastases.

Key Points: 
  • Driven to improve the lives of patients with brain tumors, a group of brain tumor specialists and medical device experts joined forces to reimagine brain brachytherapy for operable glioblastomas (GBMs), meningiomas, and brain metastases.
  • For patients with operable brain tumors, neurosurgeons seek a "maximal safe resection" of the tumor, which means they remove as much of the tumor as possible while preserving healthy brain tissue.
  • However, resecting all the brain tissue that may harbor cancer cells is limited because of the location in the brain.
  • This Surgically Targeted Radiation Therapy (STaRT) is a one-and-done radiation treatment that allows patients to get back to their daily lives sooner.

NICO Awards $40,000 Grant to Study Genetic & Biological Make-Up of Meningioma Brain Tumors

Retrieved on: 
Thursday, May 4, 2023

INDIANAPOLIS, May 4, 2023 /PRNewswire/ -- NICO Corporation, an Indianapolis-based pioneer and leader in minimally invasive neurosurgery, has awarded a $40,000 grant to Daniel Prevedello, MD, vice chair for Academic Affairs and director of Skull Base and Pituitary Surgery Programs at the Ohio State University (OSU) Comprehensive Cancer Center. The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions. Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.

Key Points: 
  • The grant supports an investigator initiated study – Circular RNA Analysis of Meningioma Invasion – aimed at providing new insight on the genetic and biological make-up of meningioma brain tumors that could ultimately guide new patient care decisions.
  • Meningiomas are the most common form of non-malignant brain tumors that are slow-growing and form along the outermost layer of tissue that covers and protects the brain and spinal cord.
  • Study on progression & recurrence of the most common brain tumor, meningioma, could guide new patient care decisions.
  • The NICO IIS grant program is dedicated to supporting novel pre-clinical and clinical research efforts related to improved patient and economic outcomes using NICO technologies.

ZAP Surgical Announces 1,000th Patient Treated with Its Groundbreaking ZAP-X Gyroscopic Radiosurgery Platform

Retrieved on: 
Wednesday, April 19, 2023

ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that the 1,000th patient has been treated with the company’s pioneering ZAP-X® Gyroscopic Radiosurgery® platform.

Key Points: 
  • ZAP Surgical Systems, Inc., a leading innovator in the field of surgical robotics, today announced that the 1,000th patient has been treated with the company’s pioneering ZAP-X® Gyroscopic Radiosurgery® platform.
  • View the full release here: https://www.businesswire.com/news/home/20230419005248/en/
    ZAP-X® Gyroscopic Radiosurgery® platform at the European Radiosurgery Center Munich, Germany (Photo: Business Wire)
    Radiosurgery is a well-established and effective treatment for many brain tumors, as well as other functional and vascular cranial diseases.
  • The milestone patient was a 57-year-old male treated for a recurrent meningioma, a tumor that arises from the membranes that surround the brain.
  • As the tumor was no longer a candidate for a second invasive surgical procedure, ZAP-X Gyroscopic Radiosurgery was ideally suited as an alternative.

HonorHealth Scottsdale Osborn Medical Center Marks an Extraordinary Milestone Treating their 100th Patient with GammaTile Therapy for Brain Tumors

Retrieved on: 
Tuesday, January 31, 2023

TEMPE, Ariz., Jan. 31, 2023 /PRNewswire/ -- GT Medical Technologies, Inc. announced that HonorHealth Scottsdale Osborn Medical Center has treated its 100th patient with GammaTile® Therapy. Since becoming the first hospital in Arizona to offer this innovative treatment option for patients with brain tumors, HonorHealth leads the country in terms of patients treated.

Key Points: 
  • TEMPE, Ariz., Jan. 31, 2023 /PRNewswire/ -- GT Medical Technologies, Inc. announced that HonorHealth Scottsdale Osborn Medical Center has treated its 100th patient with GammaTile® Therapy.
  • GammaTile is a game-changing brain tumor treatment that is implanted in the last five minutes of brain tumor removal surgery to eliminate microscopic residual tumor cells.
  • "Reaching the 100th tumor milestone for HonorHealth Scottsdale Osborn Medical Center reflects our growing experience with GammaTile use and expanding knowledge of its efficacy."
  • "This is truly a special milestone marking their 100th patient treated with GammaTile at the HonorHealth Scottsdale Osborn Medical Center.